Results 31 to 40 of about 471 (127)
β-Lactam/β-Lactamase Inhibitor Combinations in Sepsis-Associated Acute Kidney Injury and Renal Replacement Therapy [PDF]
Sepsis-associated acute kidney injury (SA-AKI) often requires renal replacement therapy (RRT), which markedly alters antimicrobial pharmacokinetics (PK) and pharmacodynamics (PD). Novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations broaden options
Antonio Lacquaniti +10 more
doaj +2 more sources
Carbapenemases in Gram-Negative Bacilli: Classification, Detection, Therapeutic Options, and Resistance to Novel Antimicrobials [PDF]
Carbapenem-resistant Gram-negative bacilli (CR-GNB), particularly Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, remain a major clinical challenge and serious threat to modern medicine, with carbapenemase production representing a
Silvana Vulpie +7 more
doaj +2 more sources
Comment on : Bonnin RA, Jeannot K, Santerre Henriksen A, Quevedo J, Dortet L. In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives. Clin Microbiol Infect. 2025 Feb;31(2):240-249. doi: 10.1016/j.cmi.2024.09.031.
Christophe, Le Terrier +3 more
openaire +3 more sources
Revitalizing cephalosporins: The promise of β-lactamase inhibitor combinations
This review explore the rise of multidrug-resistant (MDR) Gram-negative bacteria, highlighting β-lactamase inhibitor combinations as crucial therapeutic options.
Marzooka, Kazi-Chishti +4 more
doaj +2 more sources
Diagnostic algorithm for the detection of carbapenemases and extended-spectrum β-lactamases in carbapenem-resistant Pseudomonas aeruginosa [PDF]
Pseudomonas aeruginosa can acquire carbapenem resistance through various mechanisms, including genomic mutations leading to the overexpression of efflux pumps, intrinsic AmpC-β-lactamase, and/or reduced permeability, and/or through the acquisition of ...
Stefano Mancini +10 more
doaj +2 more sources
β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development
Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel ...
Angeliki Katsarou +4 more
doaj +2 more sources
In this study, we evaluated the in vitro antibacterial activity of cefepime/enmetazobactam and cefepime/zidebactam against well-characterized OXA-48-like producing Klebsiella pneumoniae clinical strains. Genomic analysis revealed that all strains carried class D carbapenemase including blaOXA-48 and blaOXA-181 as well as different ESBL genes.
Bulfoni M. +4 more
core +6 more sources
Cefepime-enmetazobactam for complicated urinary tract infections: Redefining ESBL therapy. [PDF]
Complicated urinary tract infections (UTIs) caused by extended-spectrum β-lactamase ( ESBL )- and AmpC β-lactamase-producing Enterobacterales are increasing in India, driving carbapenem use.
Chandra P.
europepmc +4 more sources
Bicyclic Boronate β‐Lactamase Inhibitors: The Present Hope against Deadly Bacterial Pathogens
This article highlights the therapeutic potential of recently developed bicyclic boronate inhibitors, such as taniborbactam (VNRX‐5133), VNRX‐7145, and QPX‐7728, for restoring the efficacy of β‐lactam antibiotics against multi‐drug resistant bacteria having distinct resistance mechanisms.
Emilio Lence +1 more
wiley +1 more source

